The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2018 | Biomarkers in lymphoma
In this interview with Arjan Diepstra, PhD, from the University of Groningen, Groningen, Netherlands, speaking from the 23rd congress of the European Haematology Association (EHA) 2018, held in Stockholm, Sweden, gives a brief overview of the role of biomarkers in lymphoma. Dr Diepstra covers how they can be used to determine patient prognosis and influence clinical decisions. He highlights the TARC biomarker currently being used in Hodgkin lymphoma.
